Patent · US Active

Subcutaneous administration of ADAMTS13

US10413600B2 · kind B2 · utility

0Cited by

0References

30Claims

0Family size

Assignee

Baxalta Incorporated · CH

Inventors

Alexandra Nathalie Kopic · Wien, AT
Werner Höllriegl · Alland, AT
Barbara Plaimauer · Wien, AT
Hanspeter Rottensteiner · Wien, AT
Eva-Maria Muchitsch · Wien, AT

Key dates

Filing date	Feb 22, 2017
Grant date	Sep 17, 2019
Priority date	—
Expiry date	Feb 22, 2037

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

This invention relates to methods of subcutaneous administration of ADAMTS13 formulations to a treat a disease or condition associated with ADAMTS13 and VWF dysfunction. Furthermore, evidence of the unexpectedly high bioavailability of ADAMTS13 formulations administered subcutaneously is provided herein.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.